Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

NCT04414163 is registered in ClinicalTrials.gov with ImmuneOncia Therapeutics Inc. as lead sponsor.

NCT NCT04414163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04414163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Lead sponsor
ImmuneOncia Therapeutics Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 27, 2020
Completion date
February 28, 2027
Enrollment
23 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal nk/t-cell lymphoma, extranodal nk/t-cell lymphoma, nasal type